Stoke is pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression. We develop antisense oligonucleotide medicines that increase gene expression to treat genetic epilepsies and other severe monogenic diseases, including genetic conditions affecting the central nervous system, eye, liver and kidney. We believe our proprietary technology platform, Targeted Augmentation of Nuclear Gene Output, or TANGO, will allow us to deliver disease-modifying therapies in a highly precise, durable and controlled manner.
December 8, 2019
December 7, 2019
November 26, 2019
Copyright West LLC. Minimum 15 minutes delayed.
December 7 - December 8, 2019
December 4, 2019 at 11:50 AM EST
November 20, 2019 at 4:10 PM EST